KNOTUS Co.Ltd (278650) - Cash Flow Conversion Efficiency
Based on the latest financial reports, KNOTUS Co.Ltd (278650) has a cash flow conversion efficiency ratio of -0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-9.34 Billion ≈ $-6.33 Million USD) by net assets (₩112.17 Billion ≈ $76.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
KNOTUS Co.Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how KNOTUS Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 278650 total liabilities for a breakdown of total debt and financial obligations.
KNOTUS Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KNOTUS Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Centrale d'Achat Française pour l'Outre-Mer Société Anonyme
PA:CAFO
|
0.140x |
|
YEAH1 Group Corp
VN:YEG
|
-0.051x |
|
DCM Corp
KO:024090
|
0.019x |
|
SANU GOLD CORP.
F:L73
|
N/A |
|
Income Opportunity Realty Investors
NYSE MKT:IOR
|
-0.001x |
|
SEOHAN Const. & Eng.co.Ltd
KQ:011370
|
0.177x |
|
Miko NV
BR:MIKO
|
0.072x |
|
Muda Holdings Bhd
KLSE:3883
|
0.000x |
Annual Cash Flow Conversion Efficiency for KNOTUS Co.Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of KNOTUS Co.Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of KNOTUS Co.Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩111.87 Billion ≈ $75.82 Million |
₩-11.67 Billion ≈ $-7.91 Million |
-0.104x | -308.10% |
| 2023-12-31 | ₩103.57 Billion ≈ $70.19 Million |
₩5.19 Billion ≈ $3.52 Million |
0.050x | -45.64% |
| 2022-12-31 | ₩70.28 Billion ≈ $47.63 Million |
₩6.48 Billion ≈ $4.39 Million |
0.092x | -29.62% |
| 2021-12-31 | ₩64.59 Billion ≈ $43.77 Million |
₩8.46 Billion ≈ $5.74 Million |
0.131x | -38.68% |
| 2020-12-31 | ₩53.64 Billion ≈ $36.35 Million |
₩11.46 Billion ≈ $7.77 Million |
0.214x | +72.64% |
| 2019-12-31 | ₩41.86 Billion ≈ $28.37 Million |
₩5.18 Billion ≈ $3.51 Million |
0.124x | -50.63% |
| 2018-12-31 | ₩20.67 Billion ≈ $14.01 Million |
₩5.18 Billion ≈ $3.51 Million |
0.251x | -22.38% |
| 2017-12-31 | ₩16.04 Billion ≈ $10.87 Million |
₩5.18 Billion ≈ $3.51 Million |
0.323x | -13.89% |
| 2016-12-31 | ₩8.36 Billion ≈ $5.66 Million |
₩3.13 Billion ≈ $2.12 Million |
0.375x | -- |
About KNOTUS Co.Ltd
HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more